Bhutan is a rapidly growing economy that is transitioning from international donor support. As such, the country is looking for ways to ensure that they continue to provide the adequate services and support for their population in a rational and sustainable manner. Bhutan has begun using health tech

Abstract Background: Diarrhoea remains one of the top ten causes of under-five child morbidity in Bhutan, and rotavirus is a significant cause of child diarrhoeal hospitalisations. This study sought to determine the health outcomes, cost-effectiveness, and budget and human resource implications o

Economic Evaluation of Rehabilitation Services for Inpatients with Stroke in Thailand: A Prospective Cohort Study. Orathai Khiaocharoen, BN, PhD1, , , , Supasit Pannarunothai, MD, PhD2, Wachara Riewpaiboon,MD3, Lily Ingsrisawang, BSc, PhD4, Yot Teerawattananon, MD, PhD5 1 Hea

Economic Evaluation of Policy Options for Prevention and Control of Cervical Cancer in Thailand Naiyana Praditsitthikorn,1,2 Yot Teerawattananon,1,3 Sripen Tantivess,1,3 Supon Limwattananon,3 Arthorn Riewpaiboon,2 Saibua Chichareon,4 Nantakan Ieumwananonthachai5 and Viroj Tangcharoensathien3

Abstract Objectives This study aims to assess the value for money and budget impact of offering hemodialysis (HD) as a first-line treatment, or the HD-first policy, and the peritoneal dialysis (PD) first policy compared to a supportive care option in patients with end-stage renal disease (ESRD)

Abstract BACKGROUND: Pegylated interferon alpha 2a, alpha 2b and ribavirin have been included to the National List of Essential Medicines (NLEM) for treatment of only chronic hepatitis C genotypes 2 and 3 in Thailand. This reimbursement policy has not covered for other genotypes of hepatitis

Economic Evaluation of Palliative Management versus Peritoneal Dialysis and Hemodialysis for End-Stage Renal Disease: Evidence for Coverage Decisions in Thailand Yot Teerawattananon1 Miranda Mugford2 Viroj Tangcharoensathien1 1Ministry of Public Health, Nonthaburi, Thailand 2University of E

Economic evaluation of HLA-B*15:02 screening for carbamazepine-induced severe adverse drug reactions in Thailand. Waranya Rattanavipapong1, Tanunya Koopitakkajorn1, Naiyana Praditsitthikorn1,2,*, Surakameth Mahasirimongkol3 andYot Teerawattananon1 Summary Purpose There is strong evidence o

Economic evaluation of HLA-B*1502 screening for preventing carbamazepine- induced Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) is prioritized by stakeholders under ‘Research for development of health benefit package under universal coverage scheme’. The study carried out an evidence to inform the Subcommittee for Developm

The objective of this study is to determine the economic evaluation of the treatment of chronic hepatitis B by using drugs that are currently available in Thailand, and to analyze the budget impact in listing drugs with cleared health economic evaluation into the National List of Essential Medicines.  01-340-2552